TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03117504

Intervention type: OTHER
Intervention: questionnaire
Description: a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.

Intervention type: OTHER
Intervention: questionnaire
Description: a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
Study: NCT03052777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counselling
Description: The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
Study: NCT00450957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04349644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE Theatre
Description: A peer-mediated, theatre-based intervention that involves 10 sessions of approximately 3 hours each that culminates in a public performance.
Study: NCT00354315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous medical education (CME)
Description: The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
Study: NCT01674725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study: NCT03860740

Intervention type: OTHER
Intervention: Exercise
Description: Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum

Intervention type: OTHER
Intervention: Stretching
Description: Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
Study: NCT02818855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Description: The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap (CAF)
Description: The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen Matrix
Description: A new collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subepithelial connective tissue graft
Description: Connective tissue graft
Study: NCT04082052

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Single Session Interventions
Description: A single session intervention either active (for self-dislike) or placebo (feelings disclosure)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Interventions
Description: A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
Study: NCT01058447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 250 mg, single dose
Study: NCT00483652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fampridine-SR
Description: Tablets, 10 mg, twice daily, 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (sugar pill)
Study: NCT02548936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe+Simvastatin Drug Combination
Description: The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
Study: NCT04184401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascites replacement with albumin and hartmann's solution
Description: Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascites replacement with hartmann's solution
Description: Hartmann's solution only strategy for ascites replacement~- 70% of ascites: replacement with Hartmann's solution
Study: NCT01283516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
Study: NCT00103454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Study: NCT00644761

Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir Dipivoxil
Description: Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
Study: NCT03309553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Primary Care Referral Process
Description: Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Referral Process
Description: In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
Study: NCT02799927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect Pulp Treatment with Bioactive Dentin Substitute
Description: The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp treatment with Calcium hydroxide
Description: The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
Study: NCT03115034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blank
Description: Patients under CEA without taking melatonin or placebo
Study: NCT00249704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D + Sham Exercise
Description: 1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitamin D Placebo + Exercise
Description: Vitamin D placebo + Exercise

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D Placebo + Sham Exercise
Description: Vitamin D placebo + Sham (equivalent to placebo) Exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D + Exercise
Description: 1000 IU per day of Vitamin D + Exercise
Study: NCT02429050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sustained release morphine
Description: Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
Study: NCT03335345

Intervention type: OTHER
Group type: OTHER
Intervention: maintaining calorie intake
Description: Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.

Intervention type: OTHER
Group type: OTHER
Intervention: maximum gastric vacuity
Description: stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
Study: NCT03054142

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT02360046

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
Study: NCT00126594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally 400 mg orally (PO) every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally 400 mg orally (PO) every 12 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10\^6 international units twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00386334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 2 mg tablet once per day in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet one per day in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet one per day in the evening.
Study: NCT01236924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural reeducation
Study: NCT04343183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
Study: NCT04587804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS+RF
Description: The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
Study: NCT03337516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling in order to assess cytarabine pharmacokinetics

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
Study: NCT04267978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin,temozolomide,irinotecan
Description: Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin,temozolomide,irinotecan
Description: Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent.
Study: NCT01658280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA
Description: Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
Study: NCT05306990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: patients followed up for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20 Mg Oral Tablet
Description: patients followed up for 3 months
Study: NCT03844841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
Study: NCT01930591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg bolus followed by 90 mg BID
Study: NCT01283516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
Study: NCT01930591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg bolus followed by 75 mg OD
Study: NCT01978457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT01937988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doula Arm
Study: NCT03435055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide Gas for Inhalation
Description: Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
Study: NCT01239797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Oral)
Description: On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (IV)
Description: On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT02431689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
Study: NCT01041859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol extended release (ER)
Description: Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= tablet, route= oral use. Matching placebo twice daily.
Study: NCT01876095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary medication review
Description: Consists of the following steps:~* 1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~* 2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~* 3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~* 5. Execution of pharmaceutical care plan according to agreed schedule.
Study: NCT02787980

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Additional taking blood
Description: Additional blood collection of 1 ml during the biological workup usually done.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Additional taking blood
Description: Additional blood collection of 1 ml during the biological workup usually done.